<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(7)</volume><submitter>Iqbal MN</submitter><funding>Vetenskapsr?det</funding><pubmed_abstract>Mesoporous silica particles (MSPs) can be used as food additives, clinically for therapeutic applications, or as oral delivery vehicles. It has also been discussed to be used for a number of novel applications including treatment for diabetes and obesity. However, a major question for their possible usage has been if these particles persist structurally and retain their effect when passing through the gastrointestinal tract (GIT). A substantial breaking down of the particles could reduce function and be clinically problematic for safety issues. Hence, we investigated the biostability of MSPs of the SBA-15 kind prepared at large scales (100 and 1000 L). The MSPs were orally administered in a murine model and clinically in humans. A joint extraction and calcination method was developed to re</pubmed_abstract><journal>ACS applied materials &amp; interfaces</journal><pagination>9542-9553</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9951217</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Mesoporous Silica Particles Retain Their Structure and Function while Passing through the Gastrointestinal Tracts of Mice and Humans.</pubmed_title><pmcid>PMC9951217</pmcid><pubmed_authors>Akhtar F</pubmed_authors><pubmed_authors>Bengtsson T</pubmed_authors><pubmed_authors>Iqbal MN</pubmed_authors><pubmed_authors>Ciurans-Oset M</pubmed_authors><pubmed_authors>Hedin N</pubmed_authors><pubmed_authors>Robert-Nicoud G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Mesoporous Silica Particles Retain Their Structure and Function while Passing through the Gastrointestinal Tracts of Mice and Humans.</name><description>Mesoporous silica particles (MSPs) can be used as food additives, clinically for therapeutic applications, or as oral delivery vehicles. It has also been discussed to be used for a number of novel applications including treatment for diabetes and obesity. However, a major question for their possible usage has been if these particles persist structurally and retain their effect when passing through the gastrointestinal tract (GIT). A substantial breaking down of the particles could reduce function and be clinically problematic for safety issues. Hence, we investigated the biostability of MSPs of the SBA-15 kind prepared at large scales (100 and 1000 L). The MSPs were orally administered in a murine model and clinically in humans. A joint extraction and calcination method was developed to re</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2026-05-28T08:15:22.588Z</modification><creation>2024-11-07T06:05:22.592Z</creation></dates><accession>S-EPMC9951217</accession><cross_references><pubmed>36731867</pubmed><doi>10.1021/acsami.2c16710</doi></cross_references></HashMap>